Controlled Studies of Metopimazine for the Treatment of Nausea and Vomiting

Moertel, Charles G.; Reitemeier, Richard J.

doi:10.1002/j.1552-4604.1973.tb00269.x

Cited by 18 publications

(11 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the phenothiazine derivatives [8], a number of other agents or their derivatives have been studied, including: trimethobenzamide [9], dimenhydrinate [5], benzquinamide [6,10], tetrahydrocannabinol [11 13], nabilone [14], metoclopramidc [15,16], halopcridol [17,18], droperidol [19], pyridoxine [6], and various gluco corticoids [20 22],…”

mentioning

confidence: 99%

Single, High-Dose Intravenous Dexamethasone as an Antiemetic in Cancer Chemotherapy

Zaglama¹,

Rosenblum²,

Sartiano³

et al. 1986

Oncology

View full text Add to dashboard Cite

The antiemetic effect of graded, single high-dose intravenous dexamethasone was studied in 27 patients receiving combination chemotherapy with either doxorubicin (50 mg/m²) or cis-platinum (100 mg/m²). A total of 57 cycles were individually evaluated, utilizing a detailed rating system. Nausea and vomiting did not occur in 20 of 57 cycles; in 17, the chemotherapy was doxorubicin-based, and in 3 it was cis-platinum-based. Of the 37 cycles associated with nausea and vomiting, 32 contained Cis-platinum and 5 doxorubicin. The average dexamethasone dosages for doxorubicin and platinum-containing combinations were 40 and 95 mg/m², respectively. Side effects included a dose-dependent sensation of perineal pruritis (11 patients, 17 cycles) lasting for serveral minutes, and subjective feelings of increased appetite and well-being. Dexamethasone administered intravenously 15 min prior to chemotherapy in a dose of 40 mg/m² apparently provides highly effective antiemetic protection for patients receiving treatment cycles containing doxorubicin; however, for patients receiving regimens containing cis-platinum, the antiemetic effect of dexamethasone as a single agent is limited.

show abstract

mentioning

confidence: 99%

Single, High-Dose Intravenous Dexamethasone as an Antiemetic in Cancer Chemotherapy

Zaglama¹,

Rosenblum²,

Sartiano³

et al. 1986

Oncology

View full text Add to dashboard Cite

show abstract

“…Prochlorperazine in oral doses of 5-10 mg!2-4, is superior to placebo [36,88] in patients receiving 5-FU, equal to metopimazine [87], equal [36] or inferior [95,105] to delta-9-tetrahydrocannabinol (THC) inferior to nabilone [5] and equal [39] or inferior [78] to dexamethasone in patients recelving various kinds of moderately emetogenic chemotherapy. In this setting a single dose of prochlorperazine 10 mg i.v.…”

Section: Phenothiazinesmentioning

confidence: 99%

Corticosteroids, dopamine antagonists and other drugs

Herrstedt

Aapro

Smyth

et al. 1998

Supportive Care in Cancer

View full text Add to dashboard Cite

show abstract

“…The dopamine D 2 receptor antagonist, metopimazine, has significant antiemetic effect as a single agent [8]. In patients receiving moderately emetogenic chemotherapy and suffering from refractory emesis, the effect of ondansetron is improved by the addition of metopimazine [9].…”

Section: Introductionmentioning

confidence: 99%

Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy

Herrstedt

Sigsgaard

Nielsen

et al. 2006

Support Care Cancer

View full text Add to dashboard Cite

Tropisetron plus metopimazine is superior to tropisetron during 4 cycles of multiple-day cisplatin-based chemotherapy, but both treatments are ineffective in a number of patients. The effect of the combination seems comparable to that of ondansetron plus dexamethasone. Newer drugs such as the neurokinin(1) receptor antagonist, aprepitant, should be investigated to optimize antiemetic therapy in patients receiving multiple-day chemotherapy.

show abstract

Controlled Studies of Metopimazine for the Treatment of Nausea and Vomiting

Cited by 18 publications

References 3 publications

Single, High-Dose Intravenous Dexamethasone as an Antiemetic in Cancer Chemotherapy

Single, High-Dose Intravenous Dexamethasone as an Antiemetic in Cancer Chemotherapy

Corticosteroids, dopamine antagonists and other drugs

Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy

Contact Info

Product

Resources

About